Opportunity Information: Apply for PA 14 136
Apply for PA 14 136
- The National Institutes of Health in the education health sector is offering a public funding opportunity titled "Prevention and Treatment of Substance Using Populations with or at Risk for HCV (R21)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.279 Drug Abuse and Addiction Research Programs 93.847 Diabetes, Digestive, and Kidney Diseases Extramural Research.
- This funding opportunity was created on Apr 7, 2014 and posted on Mar 3, 2014.
- Applicants must submit their applications by May 7, 2017. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Each selected applicant is eligible to receive up to $200,000.00 in funding.
- Eligible applicants include: County governments Native American tribal organizations (other than Federally recognized tribal governments) State governments Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education Independent school districts For profit organizations other than small businesses Native American tribal governments (Federally recognized) Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education Small businesses Special district governments Public housing authorities/Indian housing authorities Others (see text field entitled Additional Information on Eligibility for clarification) City or township governments Public and State controlled institutions of higher education Private institutions of higher education.
- Other Eligible Applicants include the following Alaska Native and Native Hawaiian Serving Institutions Asian American Native American Pacific Islander Serving Institutions (AANAPISISs) Eligible Agencies of the Federal Government Faith based or Community based Organizations Hispanic serving Institutions Historically Black Colleges and Universities (HBCUs) Indian/Native American Tribal Governments (Other than Federally Recognized) Non domestic (non U.S.) Entities (Foreign Organizations) Regional Organizations Tribally Controlled Colleges and Universities (TCCUs) U.S. Territory or Possession Non domestic (non U.S.) Entities (Foreign Institutions) are eligible to apply. Non domestic (non U.S.) components of U.S. Organizations are eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
The grant opportunity titled "Prevention and Treatment of Substance Using Populations with or at Risk for HCV (R21)" (Funding Opportunity Number PA-14-136) is a National Institutes of Health (NIH) discretionary research grant designed to support high-impact, early-stage studies that address Hepatitis C Virus (HCV) prevention and treatment among people who use substances. The core aim is to reduce new HCV infections while improving the identification, linkage to care, and treatment of people already infected, with particular attention to populations that are also infected with or at risk for HIV. The announcement emphasizes both clinical and basic research that can directly inform better interventions, service delivery approaches, and scientific understanding in real-world substance-using populations, where HCV risk and transmission can be elevated.
This funding opportunity is framed around priority areas laid out in the 2011 HHS Action Plan, "Combating the Silent Epidemic of Viral Hepatitis: Action Plan for the Prevention, Care and Treatment of Viral Hepatitis." In practical terms, that means the NIH is looking for projects that align with national public health goals such as preventing viral hepatitis transmission, improving screening and diagnosis, strengthening engagement in care, and increasing treatment uptake and success. The focus on substance-using populations reflects the disproportionate burden of HCV in groups such as people who inject drugs and others whose substance use patterns, health access barriers, or co-occurring conditions increase both acquisition risk and challenges to sustained care.
The mechanism is an R21, which is NIH's exploratory/developmental grant format. R21 awards are commonly used to test novel concepts, generate preliminary data, or evaluate innovative approaches that could later be scaled or supported through larger research mechanisms. The listed award ceiling is $200,000, and the opportunity does not require cost sharing or matching funds, which lowers the barrier for organizations that may not have the resources to contribute additional dollars. As a grant, the funding instrument supports research activities rather than contracts for predefined deliverables, leaving room for investigators to propose creative study designs that still meet the program's goals.
The announcement was posted on March 3, 2014, created on April 7, 2014, and originally closed on May 7, 2017, with the current closing date also shown as May 7, 2017. The archive date is June 7, 2017, indicating that this specific FOA is no longer active for new submissions, but it remains useful as a reference for understanding NIH priorities and for tracking how similar, newer opportunities might be structured.
Eligibility is broad and includes a wide range of public, private, nonprofit, and academic entities. Eligible applicants include state governments, county governments, city or township governments, special district governments, independent school districts, public housing authorities/Indian housing authorities, and federally recognized as well as other Native American tribal governments and organizations. Nonprofits with 501(c)(3) status and nonprofits without 501(c)(3) status are both eligible (excluding institutions of higher education in those specific nonprofit categories), and both public/state-controlled and private institutions of higher education may apply. For-profit organizations other than small businesses are eligible, and small businesses are explicitly included as well, signaling that NIH is open to applications from industry or applied research groups when the proposed work fits the research mission.
The FOA also clarifies additional eligible applicant types, including historically underserved and mission-driven institutions and organizations. These include Historically Black Colleges and Universities (HBCUs), Hispanic Serving Institutions, Tribally Controlled Colleges and Universities (TCCUs), Alaska Native and Native Hawaiian Serving Institutions, and Asian American Native American Pacific Islander Serving Institutions (AANAPISIs). Faith-based and community-based organizations may apply, as can eligible agencies of the federal government and regional organizations. Importantly, non-U.S. entities are eligible to apply, including foreign organizations and foreign institutions, and non-domestic components of U.S. organizations may participate. Foreign components are allowed as defined by the NIH Grants Policy Statement, which is relevant for studies involving international populations, cross-border collaborations, or specialized laboratory capacities located outside the United States.
From a topical standpoint, the FOA is centered on substance use and infectious disease intersection points, especially HCV and HIV. That typically points applicants toward research questions like how to prevent HCV transmission in high-risk networks, how to improve screening and early detection in settings serving people who use drugs, how to link diagnosed individuals to treatment quickly, and how to support adherence and cure in populations facing stigma, unstable housing, co-occurring mental health conditions, or ongoing substance use. The mention of both clinical and basic research suggests the NIH was interested in a spectrum ranging from intervention trials and implementation strategies to mechanistic studies that clarify how risk, immune response, co-infections, or substance-related factors influence HCV acquisition and disease course.
The opportunity falls under two CFDA numbers: 93.279 (Drug Abuse and Addiction Research Programs) and 93.847 (Diabetes, Digestive, and Kidney Diseases Extramural Research). This pairing reflects NIH's cross-institute interest in HCV within substance-using populations, covering both behavioral/addiction-related dimensions and the liver and digestive disease implications of HCV. In other words, the FOA is positioned at the intersection of addiction science, infectious disease prevention, and liver-related health outcomes, with the expectation that funded work could contribute to measurable reductions in incidence and improvements in care outcomes for populations most affected.
For applicants or researchers looking for the full archived announcement details, NIH provided an additional information link: http://grants.nih.gov/grants/guide/pa-files/PA-14-136.html. For technical access issues or broken links, the contact listed is the NIH Office of Extramural Research (OER) Webmaster at FBOWebmaster@OD.NIH.GOV.
FAQs: Prevention and Treatment of Substance Using Populations with or at Risk for HCV (R21) (PA-14-136)
What is the title and funding opportunity number for this grant?
The opportunity is titled "Prevention and Treatment of Substance Using Populations with or at Risk for HCV (R21)" and the Funding Opportunity Number is PA-14-136.
What type of funder and program is this?
This is a National Institutes of Health (NIH) discretionary research grant opportunity.
What is the main goal of the funding opportunity?
The core aim is to reduce new Hepatitis C Virus (HCV) infections while improving the identification, linkage to care, and treatment of people already infected, focusing on people who use substances. It also highlights populations that are infected with or at risk for HIV.
What populations are emphasized by this FOA?
The focus is on substance-using populations, including groups with elevated HCV risk and transmission such as people who inject drugs and others whose substance use patterns, barriers to healthcare access, or co-occurring conditions increase acquisition risk and complicate sustained care. Particular attention is given to people infected with or at risk for HIV.
What research areas or approaches does NIH want to support under this announcement?
The announcement emphasizes both clinical and basic research that can directly inform better interventions, service delivery approaches, and scientific understanding in real-world substance-using populations where HCV risk and transmission can be elevated.
How does this opportunity connect to national public health priorities?
This funding opportunity is framed around the priority areas in the 2011 HHS Action Plan, "Combating the Silent Epidemic of Viral Hepatitis: Action Plan for the Prevention, Care and Treatment of Viral Hepatitis." Projects are expected to align with goals such as preventing transmission, improving screening and diagnosis, strengthening engagement in care, and increasing treatment uptake and success.
What is the NIH activity code (grant mechanism) for this opportunity?
The mechanism is an R21, which is NIH's exploratory/developmental grant format.
What is an R21 designed to support?
R21 awards are commonly used to test novel concepts, generate preliminary data, or evaluate innovative approaches that could later be scaled or supported through larger research mechanisms.
What is the maximum award amount listed for this FOA?
The listed award ceiling is $200,000.
Does this opportunity require cost sharing or matching funds?
No. The opportunity states that it does not require cost sharing or matching funds.
Is this funding a grant or a contract?
It is a grant. The funding instrument supports research activities rather than contracts for predefined deliverables, allowing investigators to propose creative study designs that meet the program's goals.
Is the FOA currently open for new applications?
No. This FOA is archived. It originally closed on May 7, 2017 (with the current closing date also shown as May 7, 2017), and the archive date is June 7, 2017. This indicates it is no longer active for new submissions.
When was this FOA posted and created?
The announcement was posted on March 3, 2014, and created on April 7, 2014.
Why might an archived FOA still be useful?
Although it is no longer active, it can still be useful as a reference for understanding NIH priorities and for tracking how similar, newer opportunities might be structured.
Who is eligible to apply?
Eligibility is broad and includes many public, private, nonprofit, academic, and other organizational types. The FOA lists eligibility across government entities, educational institutions, nonprofits, for-profits, small businesses, tribal entities, and additional institution types described in the announcement.
Are state and local government entities eligible?
Yes. Eligible government applicants include state governments, county governments, city or township governments, special district governments, independent school districts, public housing authorities/Indian housing authorities, and regional organizations.
Are tribal governments and tribal organizations eligible?
Yes. Federally recognized Native American tribal governments, other Native American tribal governments, and Native American tribal organizations are eligible.
Are nonprofit organizations eligible?
Yes. Eligible applicants include nonprofits with 501(c)(3) status and nonprofits without 501(c)(3) status (in both cases, excluding institutions of higher education in those specific nonprofit categories, as described in the FOA).
Are colleges and universities eligible to apply?
Yes. Both public/state-controlled institutions of higher education and private institutions of higher education are eligible.
Are for-profit organizations eligible?
Yes. For-profit organizations other than small businesses are eligible, and small businesses are explicitly included as eligible applicants as well.
Are faith-based or community-based organizations eligible?
Yes. The FOA states that faith-based and community-based organizations may apply.
Are U.S. federal government agencies eligible to apply?
Yes. The FOA includes eligible agencies of the federal government among eligible applicant types.
Are non-U.S. (foreign) organizations eligible?
Yes. Non-U.S. entities are eligible to apply, including foreign organizations and foreign institutions. The FOA also notes that non-domestic components of U.S. organizations may participate.
Are foreign components allowed as part of an application?
Yes. Foreign components are allowed as defined by the NIH Grants Policy Statement, which is relevant for projects involving international populations, cross-border collaborations, or specialized laboratory capacities outside the United States.
Does the FOA highlight any historically underserved or mission-driven institution types?
Yes. It specifically lists HBCUs, Hispanic Serving Institutions, Tribally Controlled Colleges and Universities (TCCUs), Alaska Native and Native Hawaiian Serving Institutions, and Asian American Native American Pacific Islander Serving Institutions (AANAPISIs) as eligible applicant types.
What topics does the FOA center on?
The FOA centers on the intersection of substance use and infectious disease, especially HCV and HIV. It points toward studies on preventing HCV transmission, improving screening and early detection, strengthening linkage to care, and supporting treatment adherence and cure in substance-using populations facing real-world barriers.
Does the FOA allow both basic science and clinical/implementation research?
Yes. The announcement mentions both clinical and basic research, spanning intervention trials and implementation strategies as well as mechanistic studies related to risk, immune response, co-infections, substance-related factors, and HCV acquisition or disease course.
What are the CFDA numbers associated with this opportunity?
The FOA lists two CFDA numbers: 93.279 (Drug Abuse and Addiction Research Programs) and 93.847 (Diabetes, Digestive, and Kidney Diseases Extramural Research).
What does it mean that there are two CFDA numbers?
It reflects cross-institute NIH interest covering both addiction/behavioral dimensions and liver/digestive disease implications of HCV, positioning the FOA at the intersection of addiction science, infectious disease prevention, and liver-related health outcomes.
Where can applicants find the archived full announcement?
The archived NIH announcement is available at http://grants.nih.gov/grants/guide/pa-files/PA-14-136.html.
Who should be contacted for technical access issues or broken links?
The FOA lists the NIH Office of Extramural Research (OER) Webmaster for technical issues: FBOWebmaster@OD.NIH.GOV.
Browse more opportunities from the same category: Education Health
Next opportunity: Prevention and Treatment of Substance Using Populations with or at Risk for HCV (R01)
Previous opportunity: Prevention and Treatment of Substance Using Populations with or at Risk for HCV (R34)
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for PA 14 136
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (PA 14 136) also looked into and applied for these:
| Funding Opportunity |
|---|
| Prevention and Treatment of Substance Using Populations with or at Risk for HCV (R01) Apply for PA 14 137 Funding Number: PA 14 137 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Community Partnerships to Advance Research (CPAR) (R21) Apply for PA 14 141 Funding Number: PA 14 141 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Community Partnerships to Advance Research (CPAR) (R01) Apply for PA 14 142 Funding Number: PA 14 142 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Community Partnerships to Advance Research (CPAR) (R15) Apply for PA 14 140 Funding Number: PA 14 140 Agency: National Institutes of Health Category: Education Health Funding Amount: $300,000 |
| Additional Research Training Positions for NIAAA , NIDA , or NCI Supported NRSA Institutional Training (T32) Grants (Admin Supp) Apply for PA 14 146 Funding Number: PA 14 146 Agency: National Institutes of Health Category: Education Health Funding Amount: $150,000 |
| Feasibility Studies to Build Collaborative Partnerships in Cancer Research (P20) Apply for PAR 14 152 Funding Number: PAR 14 152 Agency: National Institutes of Health Category: Education Health Funding Amount: $275,000 |
| Core Infrastructure and Methodological Research for Cancer Epidemiology Cohorts (U01) Apply for PAR 14 160 Funding Number: PAR 14 160 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Effects of Cannabis Use and Cannabinoids on the Developing Brain (R03) Apply for PA 14 164 Funding Number: PA 14 164 Agency: National Institutes of Health Category: Education Health Funding Amount: $100,000 |
| Effects of Cannabis Use and Cannabinoids on the Developing Brain (R21) Apply for PA 14 162 Funding Number: PA 14 162 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Effects of Cannabis Use and Cannabinoids on the Developing Brain (R01) Apply for PA 14 163 Funding Number: PA 14 163 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Avenir Award Program for Genetics or Epigenetics of Substance Abuse (DP2) Apply for RFA DA 15 006 Funding Number: RFA DA 15 006 Agency: National Institutes of Health Category: Education Health Funding Amount: $300,000 |
| Early Phase Clinical Trials in Imaging and Image Guided Interventions (R01) Apply for PAR 14 166 Funding Number: PAR 14 166 Agency: National Institutes of Health Category: Education Health Funding Amount: $250,000 |
| Physical Sciences Oncology Centers (U54) Apply for PAR 14 169 Funding Number: PAR 14 169 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Avenir Award Program for Research on Substance Abuse and HIV/AIDS (DP2) Apply for RFA DA 15 007 Funding Number: RFA DA 15 007 Agency: National Institutes of Health Category: Education Health Funding Amount: $300,000 |
| Healthy Habits Timing for Developing Sustainable Healthy Behaviors in Children and Adolescents (R21) Apply for PA 14 176 Funding Number: PA 14 176 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Healthy Habits Timing for Developing Sustainable Healthy Behaviors in Children and Adolescents (R01) Apply for PA 14 177 Funding Number: PA 14 177 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| mHealth Tools for Underserved Populations with Chronic Conditions to Promote Effective Patient Provider Communication, Adherence to Treatment and Self Management (R01) Apply for PA 14 180 Funding Number: PA 14 180 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| mHealth Tools for Underserved Populations with Chronic Conditions to Promote Effective Patient Provider Communication, Adherence to Treatment and Self Management (R21) Apply for PA 14 181 Funding Number: PA 14 181 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| National Cooperative Drug Discovery/Development Groups (NCDDG) for the Treatment of Mental Disorders, Drug or Alcohol Addiction (U01) Apply for PAR 14 184 Funding Number: PAR 14 184 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Revisions to Add Biomedical Big Data Training to Active NLM Institutional Training Grants in Biomedical Informatics (T15) Apply for RFA HG 14 006 Funding Number: RFA HG 14 006 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "PA 14 136", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.